TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00975611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets BID, for 4 weeks
Study: NCT02056015
Drug: [68Ga]MLN6907
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Administration of \[68Ga\]MLN6907 on Day 1
Study: NCT00612274
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
Study: NCT00813150
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
Study: NCT02772211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
Study: NCT00454688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
Study: NCT03368092
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
Study: NCT00298272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo on Day 1 and Day 15
Study: NCT00298272
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
Study: NCT02503124
Drug: Treatment as usual - medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
Study: NCT02527746
Drug: EC regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
Study: NCT00858455
Drug: GSK1349572 and MaaloxAdvanced Maximum Strength
Normalized name: Ivarest Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
Study: NCT00858455
Drug: GSK1349572 and Maalox Advanced Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
Study: NCT00858455
Drug: GSK1349572 and One A Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
Study: NCT00858455
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of GSK1349572
Study: NCT00388726
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Study: NCT04849468
Drug: Declofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
Study: NCT00833495
Drug: Prednisolone Acetate 0.12% (Pred Mild®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
Study: NCT00833495
Drug: FOV1101-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
Study: NCT00833495
Drug: Prednisolone Acetate 1% (Pred Forte®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
Study: NCT00833495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
Study: NCT01616238
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
Study: NCT02057133
Drug: LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02057133
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy administered orally.
Study: NCT03213002
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1500 mg/m2
Study: NCT05919732
Drug: Bupivacaine, Dexmedetomidine, Caffeine, Tylenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
Study: NCT01011751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
Study: NCT00439712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet OD in the morning for 29+/-4 days
Study: NCT01513720
Drug: Lamictal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamictal® 200 mg Tablets
Study: NCT01135329
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV daily on Day +3 and Day +4.
Study: NCT00839800
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/4.5 µg
Study: NCT00474071
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Detailed Description.
Study: NCT03448419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01698892
Drug: I.V Sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
Study: NCT01698892
Drug: sublingual sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
Study: NCT03058562
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02982681
Drug: Bioactive Glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control site were packed with the bioactive glass graft alone
Study: NCT02604992
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol oral solution, under fed conditions
Study: NCT02604992
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol oral capsule, under fed conditions
Study: NCT05919732
Drug: Propofol, rocuronium, caffeine, Tylenol, bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)
Study: NCT00703690
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0767 2.5, 5, and 10 mg/day supplied as tablets
Study: NCT01588158
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg
Study: NCT02914613
Drug: SF0166 Topical Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00018564
Drug: treatments for essential tremor
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04349228
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Hydroxychloroquine (HCQ) without any active substance
Study: NCT03378674
Drug: Remifentanil Injectable Product
Normalized name: remifentanil Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil: 0,15 mcg/kg/min
Study: NCT00740792
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo one spray per nostril BID
Study: NCT03293992
Drug: 0.01% RO7058584
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily morning administration for 7 days
Study: NCT03293992
Drug: 0.1% RO7058584
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily morning administration for 7 days
Study: NCT03293992
Drug: 1% RO7058584
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily morning administration for 7 days
Study: NCT03293992
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily morning administration for 7 days
Study: NCT01709682
Drug: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
Study: NCT04244084
Drug: MMH-407
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use.
Study: NCT04244084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use.
Study: NCT01052194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, placebo b.i.d. for 12 weeks
Study: NCT00501410
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 by vein on day 1.
Study: NCT03192306
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solution
Study: NCT02417142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SQ 1x/week for 24 weeks.
Study: NCT04164732
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 orally twice daily
Study: NCT04164732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03755557
Drug: Budesolv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a nasal spray
Study: NCT01871844
Drug: ITF2984 (500, 1000, 2000 mcg bid for 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01160848
Drug: Area cleaned with Ethyl alcohol solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01160848
Drug: Visonac left on the skin for 24 hours in facial area one
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03221816
Drug: Tenavit®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group received one tablet of Tenavit® daily for a period of 4 months.
Study: NCT03221816
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
Study: NCT01602861
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).
Study: NCT01602861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00027066
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325mg aspirin placebo pill
Study: NCT02861222
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03768258
Drug: Testosterone Implant
Normalized name: Testosterone Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
Study: NCT01313286
Drug: LY2608204 Reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01313286
Drug: LY2608204 Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02283281
Drug: Dummy oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
Study: NCT03074058
Drug: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)
Normalized name: Fosrenol Chewable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
Study: NCT00979316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
Study: NCT01278004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03136640
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT03682848
Drug: DTG + 3TC FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
Study: NCT02011633
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study: NCT00295022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use
Study: NCT02744729
Drug: 99mTc-3PRGD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study: NCT02976740
Drug: Immunological Agent
Normalized name: IMMUNOLOGICAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
Study: NCT02976740
Drug: Immunological Factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
Study: NCT00154284
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Study: NCT02084043
Drug: Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
Study: NCT02084043
Drug: Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
Study: NCT01594736
Drug: ORSIRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: due randomization ORSIRO will be implanted
Study: NCT03806933
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
Study: NCT00078767
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
Study: NCT00596687
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
Study: NCT01722825
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03831113
Drug: Magnitude Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Study: NCT03831113
Drug: Frequency Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Study: NCT00172172
Drug: PTH/Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) subcutaneous injection and calcium 700 mg oral
Study: NCT00172172
Drug: PTH/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH (1-84) injected subcutaneously and placebo provided orally
Study: NCT00172172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously and 700 mg calcium orally
Study: NCT01455597
Drug: WC3011 Estradiol Vaginal Cream
Normalized name: Estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
Study: NCT00607074
Drug: Control group (placebo)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Study: NCT01469130
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
Study: NCT00857090
Drug: OMS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery
Study: NCT00857090
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stages 1-2: Vehicle irrigation solution during surgery
Study: NCT00002691
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002691
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002691
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01225016
Drug: Definity contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid ultrasound using contrast agent
Study: NCT01069510
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 12 months
Study: NCT02282813
Drug: CTAP101 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
Study: NCT02506556
Drug: BYl719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days
Study: NCT00532389
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04346667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care plus placebo
Study: NCT02748642
Drug: BITS7201A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Study: NCT02748642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.